Methylphenidate Formulation Modeled to Maximize Benefit in ADHD
A proposed novel modeling of an oral methylphenidate formulation for attention-deficit/hyperactivity disorder (ADHD) goes beyond the traditional relating of in-vitro dissolution and drug release with in-vivo serum drug levels, to specify the amount and time of drug release which can best evoke clinical benefit.
Other Articles in this Edition
Few US Children with ADHD Receive Recommended Psychosocial Treatment
ACCESS Therapy Shows Promise for College Students with ADHD
CBT for Adult ADHD: Getting Patients to Do What They Know They Need to Do
New Ways of Thinking About ADHD and Cognition at 2018 APSARD Annual Meeting
Rarity of Late-Onset ADHD: Symptoms Linked to Other Causes
Formulation-Based CBT Improves Symptoms, Functioning in Adults With ADHD
Medicaid Prior Authorization Policies Impact ADHD Treatments
Psychologist Barkley Says Life Expectancy Slashed in Worst Cases for Those With ADHD
Methylphenidate Formulation Modeled to Maximize Benefit in ADHD